Home
HelpTest Code MANN Alpha-Mannosidase, Leukocytes
Reporting Name
Alpha-Mannosidase, LeukocytesUseful For
Diagnosis of alpha-mannosidosis
This test is not useful for establishing carrier status for alpha-mannosidosis.
Performing Laboratory
Mayo Clinic Laboratories in Rochester
Specimen Type
Whole Blood ACDOrdering Guidance
If clinically suspicious of an oligosaccharidosis, a screening test is available. Order OLIGU / Oligosaccharide Screen, Random, Urine.
Shipping Instructions
For optimal isolation of leukocytes, it is recommended the specimen arrive refrigerate within 6 days of collection to be stabilized. Collect specimen Monday through Thursday only and not the day before a holiday. Specimen should be collected and packaged as close to shipping time as possible.
Specimen Required
Container/Tube:
Preferred: Yellow top (ACD solution B)
Acceptable: Yellow top (ACD solution A)
Specimen Volume: 6 mL
Collection Instructions: Send specimen in original tube. Do not aliquot.
Specimen Minimum Volume
5 mL
Specimen Stability Information
| Specimen Type | Temperature | Time | Special Container |
|---|---|---|---|
| Whole Blood ACD | Refrigerated (preferred) | 6 days | YELLOW TOP/ACD |
| Ambient | 6 days | YELLOW TOP/ACD |
Special Instructions
Reference Values
≥0.54 nmol/min/mg protein
Day(s) Performed
Preanalytical processing: Monday through Saturday
Assay performed: Once per month
Test Classification
This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.CPT Code Information
82657
LOINC Code Information
| Test ID | Test Order Name | Order LOINC Value |
|---|---|---|
| MANN | Alpha-Mannosidase, Leukocytes | 24053-1 |
| Result ID | Test Result Name | Result LOINC Value |
|---|---|---|
| 35639 | Alpha-Mannosidase, Leukocytes | 24053-1 |
| 35640 | Interpretation (MANN) | 59462-2 |
| 35641 | Reviewed By | 18771-6 |
Interpretation
Values below 0.54 nmol/min/mg protein are consistent with a diagnosis of alpha-mannosidosis.
Clinical Reference
1. Malm D, Nilssen O: Alpha-mannosidosis. In: Adam MP, Ardinger HH, Pagon RA, et al, eds. GeneReviews [Internet]. University of Washington, Seattle. 2001. Updated July 18, 2019. Accessed February 18, 2022. Available at www.ncbi.nlm.nih.gov/books/NBK1396/
2. Thomas GH: Disorders of glycoprotein degradation: alpha-mannosidosis, beta-mannosidosis, fucosidosis, and sialidosis. In: Valle DL, Antonarakis S, Ballabio A, Beaudet AL, Mitchell GA eds. The Online Metabolic and Molecular Bases of Inherited Disease. McGraw-Hill; 2019. Accessed February 18, 2022. Available at https://ommbid.mhmedical.com/content.aspx?sectionid=225545029
3. Mynarek M, Tolar J, Albert MH, et al: Allogeneic hematopoietic SCT for alpha-mannosidosis: an analysis of 17 patients. Bone Marrow Transplant. 2012 Mar;47(3):352-359. doi: 10.1038/bmt.2011.99
4. Guffon N, Tylki-Szymanska AT, Borgwardt L, et al: Recognition of alpha-mannosidosis in paediatric and adult patients: Presentation of a diagnostic algorithm from an international working group. Mol Genet Metab. 2019 Apr;126(4):470.474. doi: 10.1016/j.ymgme.2019.01.024
Report Available
30 to 45 daysMethod Name
Fluorometric
Forms
1. New York Clients-Informed consent is required. Document on the request form or electronic order that a copy is on file. The following documents are available:
-Informed Consent for Genetic Testing (T576)
-Informed Consent for Genetic Testing-Spanish (T826)
2. Biochemical Genetics Patient Information (T602)
3. If not ordering electronically, complete, print, and send a Biochemical Genetics Test Request (T798) with the specimen.